RXST vs STAA
RXST: RxSight offers the only premium cataract surgery system that allows doctors to customize and optimize visual acuity for patients post-surgery using a light-adjustable lens. STAA: STAAR Surgical is a medical device company focused on vision correction through its proprietary implantable lens technology.
Side-by-side fundamentals
| Metric | RXST | STAA | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $4.90 | $21.61 | |
| Market cap | $204M | $1.1B | |
| P/E as of 2026-10-21 | n/a | 270.13 | |
| Net margin | -29.0% | -33.6% | RXST higher |
| Gross margin | +76.6% | +76.2% | RXST higher |
| Operating margin | -35.8% | -38.3% | RXST higher |
| ROE | -14.1% | -23.4% | RXST higher |
| ROA | -12.5% | -17.8% | RXST higher |
| Revenue growth (YoY) FY2025, SEC XBRL | -3.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +40.0% | +0.0% | RXST higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.12 | 0.61 | |
| 1-year return as of 2026-10-21 close | -43.7% | -19.0% | STAA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.